quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:10:58·52d
SECFiling
Amylyx Pharmaceuticals Inc. logo

SEC Form 10-K filed by Amylyx Pharmaceuticals Inc.

AMLX· Amylyx Pharmaceuticals Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • AMLX
    Amylyx Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Mar 3UpdateStifel$21.00
  • Jul 10UpdateGoldman$10.00
  • Jun 24UpdateGuggenheim$17.00
  • Jun 17UpdateCitigroup$12.00
  • May 30UpdateTD Cowen-
  • Apr 7UpdateMizuho$7.00

Related

  • SEC1d
    SEC Form DEFA14A filed by Amylyx Pharmaceuticals Inc.
  • SEC1d
    SEC Form DEF 14A filed by Amylyx Pharmaceuticals Inc.
  • PR16d
    Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Amylyx Pharmaceuticals Inc.
  • SEC31d
    Amylyx Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure
  • PR31d
    Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
  • INSIDER45d
    Chief Financial Officer Frates James M was granted 95,990 shares, increasing direct ownership by 58% to 261,628 units (SEC Form 4)
  • INSIDER45d
    Chief Legal Officer Mazzariello Gina was granted 74,660 shares, increasing direct ownership by 56% to 209,090 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022